Noninvasive small-animal imaging of galectin-1 upregulation for predicting tumor resistance to radiotherapy.
Noninvasive small-animal imaging of galectin-1 upregulation for predicting tumor resistance to radiotherapy.
复制标题
DOI：
10.1016/j.biomaterials.2017.12.012
复制
发表时间：
2018-03
期刊：
影响因子：
14
通讯作者：
Jianhao Lai;D. Lu;Chenran Zhang;Hua Zhu;Liquan Gao;Yanpu Wang;Rui Bao;Yang Zhao;Bing Jia;Fan Wang;Zhi Yang;Zhaofei Liu
中科院分区：
文献类型：
--
作者：
Jianhao Lai;D. Lu;Chenran Zhang;Hua Zhu;Liquan Gao;Yanpu Wang;Rui Bao;Yang Zhao;Bing Jia;Fan Wang;Zhi Yang;Zhaofei Liu
Increasing evidence indicates that the overexpression of galectin-1, a member of the galectin family, is related to tumor progression and invasion, as well as tumor resistance to therapies (e.g., radiotherapy). Herein, we investigated whether near-infrared fluorescence (NIRF) imaging and positron-emission tomography (PET) were sensitive approaches for detecting and quantitating galectin-1 upregulationin vivo. An anti-galectin-1 antibody was labeled with either an NIRF dye or64Cu, and NIRF and PET imaging using the resulting probes (Dye-αGal-1 and64Cu- 1,4,7-triazacyclononane-1,4,7-triacetic acid [NOTA]-αGal-1) were performed in 4T1 breast cancer-bearing mice treated with several rounds of sorafenib. Radiotherapy was performedin vitroandin vivoto identify the role of galectin-1 in radioresistance. NIRF and PET imaging both revealed significantly increased upregulation of galectin-1 in the hypoxic tumors after sorafenib treatment, which was verified byex vivobiodistribution, western blotting, and enzyme-linked immunosorbent assays. Galectin-1 specific inhibition by thiodigalactoside dramatically improved the efficacy of radiotherapy, and overcame sorafenib-induced radiotherapy resistance. Taken together, galectin-1 is a key mediator of tumor resistance to radiotherapy. Targeted molecular imaging allows for real-time, noninvasive, and quantitative detection of the dynamic changes in galectin-1 levelsin vivo;this introduces the possibility of early detection of tumor resistance to therapies.
